TAFI and pancreatic carboxypeptidase B modulate in vitro capillary tube formation by human microvascular endothelial cells

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 27, Issue 10, 2007, Pages 2157-2162

  Guimarães, Ana H C ^a,b   Laurens, Nancy ^a   Weijers, Ester M ^a   Koolwijk, Pieter ^a,c   Van Hinsbergh, Victor W M ^a   Rijken, Dingeman C ^b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c TNO   (Netherlands)

Author keywords

Angiogenesis; Carboxypeptidase B; Plasma clot matrix; Plasminogen; TAFI

Indexed keywords

CARBOXYPEPTIDASE B; FIBRIN DEGRADATION PRODUCT; MATRIX PROTEIN; PLASMINOGEN; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; ANGIOGENESIS INHIBITOR; CARBOXYPEPTIDASE INHIBITOR, PLANT; FIBRIN; FIBROBLAST GROWTH FACTOR 2; PROTEINASE INHIBITOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UROKINASE; VEGETABLE PROTEIN;

ANGIOGENESIS; ARTICLE; ATHEROSCLEROTIC PLAQUE; BLOOD CLOT; CAPILLARY; CELL ADHESION; CELL MOTION; CELL PROLIFERATION; CELL STIMULATION; CELL SURFACE; CONTROLLED STUDY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MICROVASCULATURE; MODULATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN SECRETION; ATHEROSCLEROSIS; CELL CULTURE; CULTURE TECHNIQUE; CYTOLOGY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; METABOLISM; TIME; WOUND HEALING;

ANGIOGENESIS INHIBITORS; ATHEROSCLEROSIS; CAPILLARIES; CARBOXYPEPTIDASE B; CARBOXYPEPTIDASE U; CELL ADHESION; CELL CULTURE TECHNIQUES; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL CELLS; FIBRIN; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FIBROBLAST GROWTH FACTOR 2; HUMANS; NEOVASCULARIZATION, PHYSIOLOGIC; PLANT PROTEINS; PLASMINOGEN; PROTEASE INHIBITORS; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA; URINARY PLASMINOGEN ACTIVATOR; WOUND HEALING;

EID: 35148845916     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.107.150144     Document Type: Article

References (37)

1. Bouma BN, Marx PF, Mosnier LO, Meijers JC. Thrombin-activatable fibrinolysis inhibitor (TAFI, plasma procarboxypeptidase B, procarboxypeptidase R, procarboxypeptidase U). Thromb Res. 2001;101:329-354.
2. Marx PF. Thrombin-activatable fibrinolysis inhibitor. Curr Med Chem. 2004;11:2335-2348.
3. Wang W, Hendriks DF, Scharpe SS. Carboxypeptidase U, a plasma carboxypeptidase with high affinity for plasminogen. J Biol Chem. 1994;269:15937-15944.
4. Barbosa Pereira PJ, Segura-Martin S, Oliva B, Ferrer-Orta C, Aviles FX, Coll M, Gomis-Ruth FX, Vendrell J. Human procarboxypeptidase B: three-dimensional structure and implications for thrombin-activatable fibrinolysis inhibitor (TAFI). J Mol Biol. 2002;321:537-547.
5. Carmeliet P, Collen D. Role of the plasminogen/plasmin system in thrombosis, hemostasis, restenosis and atherosclerosis. - Evaluation in Transgenic Animals. Trends Cardiovasc Med. 1995;5:117-122.
6. Sakharov DV, Rijken DC. Superficial accumulation of plasminogen during plasma clot lysis. Circulation. 1995;92:1883-1890.
7. Suenson E, Lutzen O, Thorsen S. Initial plasmin-degradation of fibrin as the basis of a positive feed-back mechanism in fibrinolysis. Eur J Biochem. 1984;140:513-522.
8. Sakharov DV, Plow EF, Rijken DC. On the mechanism of the antifibrinolytic activity of plasma carboxypeptidase B. J Biol Chem. 1997;272:14477- 14482.
9. Broze GJ Jr, Higuchi DA. Coagulation-dependent inhibition of fibrinolysis: role of carboxypeptidase-U and the premature lysis of clots from hemophilic plasma. Blood. 1996;88:3815-3823.
10. Guimarães AHC, Rijken DC. Thrombin activatable fibrinolysis inhibitor (TAFI) affects fibrinolysis in a plasminogen activator concentration-dependent manner. Study of seven plasminogen activators in an internal clot lysis model. Thromb Haemost. 2004;91:473-479.
11. Refino CJ, DeGuzman L, Schmitt D, Smyth R, Jeet S, Lipari MT, Eaton D, Bunting S. Consequences of inhibition of plasma carboxypeptidase B on in vivo thrombolysis, thrombosis and hemostasis. Fibrinolysis & Proteolysis. 2000;14:305-314.
12. Nagashima M, Werner M, Wang M, Zhao L, Light DR, Pagila R, Morser J, Verhallen P. An inhibitor of activated thrombin-activatable fibrinolysis inhibitor potentiates tissue-type plasminogen activator-induced thrombolysis in a rabbit jugular vein thrombolysis model. Thromb Res. 2000;98:333-342.
13. Klement P, Liao P, Bajzar L. A novel approach to arterial thrombolysis. Blood. 1999;94:2735-2743.
14. Bjorkman JA, Abrahamsson TI, Nerme VK, Mattsson CJ. Inhibition of carboxypeptidase U (TAFIa) activity improves rt-PA induced thrombolysis in a dog model of coronary artery thrombosis. Thromb Res. 2005;116:519-524.
15. Miles LA, Dahlberg CM, Plescia J, Felez J, Kato K, Plow EF. Role of cell-surface lysines in plasminogen binding to cells: identification of alpha-enolase as a candidate plasminogen receptor. Biochemistry. 1991;30:1682-1691.
16. Collen A, Koolwijk P, Kroon M, van Hinsbergh VWM. Influence of fibrin structure on the formation and maintenance of capillary-like tubules by human microvascular endothelial cells. Angiogenesis. 1998;2:153-165.
17. Kikuchi Y, Oomori K, Kizawa I, Hirata J, Kita T, Miyauchi M, Kato K. Enhancement of antineoplastic effects of cisplatin by calmodulin antagonists in nude mice bearing human ovarian carcinoma. Cancer Res. 1987;47:6459-6461.
18. Sigurdsson K, Johnsson JE, Trope C. Tranexamic acid for the treatment of advanced ovarian carcinoma. Acta Obstet Gynecol Scand. 1983;62:265-266.
19. Redlitz A, Tan AK, Eaton DL, Plow EF. Plasma carboxypeptidases as regulators of the plasminogen system. J Clin Invest. 1995;96:2534-2538.
20. Nagashima M, Yin ZF, Zhao L, White K, Zhu Y, Lasky N, Halks-Miller M, Broze GJ Jr, Fay WP, Morser J. Thrombin-activatable fibrinolysis inhibitor (TAFI) deficiency is compatible with murine life. J Clin Invest. 2002;109:101-110.
21. Swaisgood CM, Schmitt D, Eaton D, Plow EF. In vivo regulation of plasminogen function by plasma carboxypeptidase B. J Clin Invest. 2002;110:1275-1282.
22. te Velde EA, Wagenaar GT, Reijerkerk A, Roose-Girma M, Borel Rinkes I, Voest EE, Bouma BN, Gebbink MF, Meijers JC. Impaired healing of cutaneous wounds and colonic anastomoses in mice lacking thrombin-activatable fibrinolysis inhibitor. J Thromb Haemost. 2003;1:2087-2096.
23. Koolwijk P, van Erck MG, de Vree WJ, Vermeer MA, Weich HA, Hanemaaijer R, van Hinsbergh VWM. Cooperative effect of TNFalpha, bFGF, and VEGF on the formation of tubular structures of human microvascular endothelial cells in a fibrin matrix. Role of urokinase activity. J Cell Biol. 1996;132:1177-1188.
24. van Hinsbergh VW, Koolwijk P, Hoekman K. The hemostatic system in angiogenesis. EXS 2005;247-266.
25. van Hinsbergh VW, Engelse MA, Quax PH. Pericellular proteases in angiogenesis and vasculogenesis. Arterioscler Thromb Vasc Biol. 2006;26:716-728.
26. Dvorak HF, Harvey VS, Estrella P, Brown LF, McDonagh J, Dvorak AM. Fibrin containing gels induce angiogenesis. Implications for tumor stroma generation and wound healing. Lab Invest. 1987;57:673-686.
27. Conway EM. Angiogenesis: a link to thrombosis in athero-thrombotic disease. Pathophysiol Haemost Thromb. 2003;33:241-248.
28. Modarai B, Burnand KG, Humphries J, Waltham M, Smith A. The role of neovascularisation in the resolution of venous thrombus. Thromb Haemost. 2005;93:801-809.
29. Guimarães AHC, Barrett-Bergshoeff MM, Gils A, Declerck PJ, Rijken DC. Migration of the activation peptide of thrombin-activatable fibrinolysis inhibitor (TAFI) during SDS-polyacrylamide gel electrophoresis. J Thromb Haemost. 2004;2:780-784.
30. Guimarães AHC, Bertina RM, Rijken DC. A new functional assay of thrombin activatable fibrinolysis inhibitor. J Thromb Haemost. 2005;3:1284-1292.
31. van Hinsbergh VWM, Sprengers ED, Kooistra T. Effect of thrombin on the production of plasminogen activators and PA inhibitor-1 by human foreskin microvascular endothelial cells. Thromb Haemost. 1987;57:148-153.
32. Carmeliet P, Schoonjans L, Kieckens L, Ream B, Degen J, Bronson R, De Vos R, van den Oord JJ, Collen D, Mulligan RC. Physiological consequences of loss of plasminogen activator gene function in mice. Nature. 1994;368:419-424.
33. Lijnen HR, Okada K, Matsuo O, Collen D, Dewerchin M. Alpha2-antiplasmin gene deficiency in mice is associated with enhanced fibrinolytic potential without overt bleeding. Blood. 1999;93:2274-2281.
34. Rømer J, Bugge TH, Pyke C, Lund LR, Flick MJ, Degen JL, Danø K. Impaired wound healing in mice with a disrupted plasminogen gene. Nat Med. 1996;2:287-292.
35. Lund LR, Rømer J, Bugge TH, Nielsen BS, Frandsen TL, Degen JL, Stephens RW, Danø K. Functional overlap between two classes of matrix-degrading proteases in wound healing. EMBO J. 1999;18:4645-4656.
36. Herren T, Swaisgood C, Plow EF. Regulation of plasminogen receptors. Front Biosci. 2003;8:d1-d8.
37. Mao SS, Cooper CM, Wood T, Shafer JA, Gardell SJ. Characterization of plasmin-mediated activation of plasma procarboxypeptidase B. Modulation by glycosaminoglycans. J Biol Chem. 1999;274:35046-35052.